<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80511">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785147</url>
  </required_header>
  <id_info>
    <org_study_id>P12-01 / BP1.4979</org_study_id>
    <secondary_id>2012-002731-28</secondary_id>
    <nct_id>NCT01785147</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BP1.4979 in Smoking Cessation</brief_title>
  <official_title>Randomized Placebo Controlled Trial Assessing the Efficacy and Safety of BP1.4979 in Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study which aim is to assess in heavy smokers willing to quit smoking the efficacy
      and the safety profile of BP1.4979 for smoking cessation on the total abstinence measured by
      subject diary and confirmed by exhaled CO (abstinent &lt; 10 ppm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BP1.4979 is a novel compound with promising efficacy on smoker which have been assessed on
      phase I studies.

      This is a multicenter,randomized, double blind,  placebo controlled, phase IIb trial with
      parallel group to assess safety and efficacy of BP1.4979 in smoker.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>4-week prolonged abstinence from smoking cigarettes</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary measure of efficacy will be 4-week prolonged abstinence from smoking cigarettes at the end of 12-week double-blind treatment phase (i.e. from V3 to V4).
The continuous abstinence measured by subject diary and verified by exhaled CO (abstinent &lt; 10 ppm) will define response to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>7-day tobacco Point Prevalence Abstinence (PPA)</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>7-day tobacco Point Prevalence Abstinence (PPA) will be assessed at each visit by analysis of cigarettes consumption using self-report diaries and measurement of exhaled CO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of safety thanks to the number and clinical evaluation of the adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs measures</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs (measurement of heart rate, blood pressure, and body weight) will be assessed at each study visit, thanks to physical examinations (V0 and V4), ECG and laboratory tests (blood chemistry, haematology, urinanalysis tests, prolactin dosage) at screening (V0), after 4-week treatment (V2) and at V4.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Tobacco Addiction</condition>
  <arm_group>
    <arm_group_label>BP1.4979 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BP1.4979 3mg during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BP1.4979 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BP1.4979 10mg during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BP1.4979 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BP1.4979 15mg during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo during 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP1.4979</intervention_name>
    <description>BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.</description>
    <arm_group_label>BP1.4979 3mg</arm_group_label>
    <arm_group_label>BP1.4979 10mg</arm_group_label>
    <arm_group_label>BP1.4979 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  a smoking history of at least 10 years

          -  subject smoking at least 15 cigarettes per day at the time being  and for at least 30
             days before selection.

          -  having already made at least 2 attempts to stop

          -  with no period of abstinence &gt; 3 months in the previous year

          -  FTND ≥ 7

        Main exclusion Criteria:

          -  any significant psychiatric illness or mood disorder, assessed by the BDI

          -  HAD scale (A + D ≥ 19, the day of the selection and inclusion)

          -  AUDIT ≥ 8

          -  subject smoking cigars or pipes exclusively

          -  subject taking any antismoking medication and/ or  Nicotine Replacement Therapy (NRT)
             in the previous month.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri-Jean AUBIN, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Paul Brousse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Lecomte, M.D.</last_name>
    <phone>0033 (0)1 47 03 66 33</phone>
    <email>i.lecomte@bioprojet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <state>Ile de France</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri-Jean AUBIN, MD, Ph.D</last_name>
      <phone>+33 (0)1 45 59 30 00</phone>
    </contact>
    <investigator>
      <last_name>Henri-Jean AUBIN, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobacco addition</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
